DRD2-mediated preclinical efficacy of ONC206 in endometrial cancer
ONC206 is effective in preclinical models of an aggressive subtype of endometrial cancer due to DRD2 antagonism. Please find the full paper here.
ONC206 is effective in preclinical models of an aggressive subtype of endometrial cancer due to DRD2 antagonism. Please find the full paper here.
This pan-tumor liquid biopsy test will include testing for the H3 K27M mutation. Please find more information here.
Please find the full article here.
Please find the full article here.